Introduction: Osteoarthritis (OA) constitutes a
shown to be more effective in earlier stages and grades of disease, more recently diagnosed OA, and in less severe radiographic OA.
Conclusion:
For primary care physicians who treat and care for patients with OA of the knee,
INTRODUCTION
Osteoarthritis (OA) is a chronic condition that causes pain and substantial disability [1] . It primarily affects the hands, knees, and hips, severely limiting the daily activity and quality of life for many individuals in the United States (US) [1] . Approximately 25% of people with pain from knee OA experience difficulty performing major activities of daily living, including walking a quarter mile, climbing stairs, and kneeling [1] . In addition, 15% use an assistive device in order to walk [2] . OA constitutes a growing public health burden [1] and represents the most common cause of disability in the US [1, 3] . Nearly one million years are lived with disability from knee and hip OA, making it the third leading cause of years lived with a disability in the US [1] . OA is highly prevalent and affects over 27 million Americans [1] . Because OA accounts for 630,000 joint replacements and 11 million outpatient visits annually [1] , it generates staggering socioeconomic costs. In addition, OA impedes work productivity, accounting for more than 13 billion dollars in job-related costs [1] . OA is not caused by normal aging, but its prevalence increases with age [1, 4] , rising sharply at 45 years old and affecting a large proportion of the working population [1] . With the well documented aging of the US population, the prevalence and burden of OA is expected to increase in the coming years due to longer life expectancies and the first of more than 78 million baby boomers reaching retirement age in 2011 [1] . Half of all US adults will develop symptomatic OA in their lives [1, 5] and as more adults continue to work beyond age 65, OA will likely further impair their work quality and ability to engage in retirement activities without pain and disability [1] .
Another major factor contributing to the rise in OA prevalence is the obesity epidemic [1] . Weight increases OA risk and it is, therefore, not surprising that arthritis is highly prevalent among obese adults [1, 3, 6] . Ultimately, two of every three obese adults can be expected to develop OA in their lifetime [1] . 
OVERVIEW OF OA PATHOPHYSIOLOGY
Osteoarthritis is a disorder of the entire joint that affects all joint tissues that communicate at the cellular level by releasing and responding to inflammatory mediators [4] . Cartilage destruction is the hallmark of OA and the degradation of type II collagen is the pivotal event that leads to irreversible progression of OA [4] . The balance that exists between matrix synthesis and degradation in normal cartilage is disrupted in OA by several factors produced by the synovium and chondrocytes, including cytokines, growth factors, aggrecanases, and matrix metalloproteinases (MMPs) [7] . In OA, the viscosity and elasticity of synovial fluid is much lower due to decreases in endogenous hyaluronan concentration and molecular weight [8, 9] ; this impairs the ability of synovial fluid to lubricate joints, absorb loads, and exert anti-inflammatory effects.
Although the mechanism of the inflammatory process in OA is unknown, abnormal mechanical and oxidative stresses are likely involved [4] . Three mechanical risk factors have been found to strongly correlate with cartilage loss: malalignment of the tibiofemoral joint, bone marrow lesions, and meniscal disease manifested either as a tear or as extrusion [10] .
Inflammation of the synovium is a trigger for various symptoms of OA by releasing soluble factors that, while increasing and perpetuating cartilage damage, have the potential to be used as biomarkers [3] . Synovial inflammation also triggers changes in the peripheral nervous system, affecting the afferent processing of nociceptive signals from the joint and surrounding tissues [7, 10] . Inflammation may also contribute to perpetuating cartilage degradation by promoting destruction and impairing repair [4] . In addition, impaired proprioceptive acuity may be involved in OA pathogenesis, as proprioceptive deficits are greater in people with knee OA compared with people of a similar age without OA [10] . used to treat knee OA because they are inexpensive and readily available over the counter [14] . Research has shown that both acetaminophen and NSAIDs produce small-tomoderate effect sizes (0.13-0.44) with regard to pain relief [12] .
TREATMENT OPTIONS FOR OA
The systemic safety of acetaminophen and NSAIDs including cyclooxygenase-2 (COX-2) inhibitors has come into question by the Food and Drug Administration (FDA) and clinicians [15] [16] [17] [18] . Excessive doses of acetaminophen can be hepatotoxic [15] , and NSAIDs are associated with a wide spectrum of adverse effects, including gastrointestinal (GI) complications, renal toxicity, hepatotoxicity, and cardiovascular (CV) events, the risk of which increases in the presence of chronic comorbidities that are common among older patients with OA [18] . The risk of adverse side effects with chronic NSAID use increases with age, dose and duration of exposure [3, [16] [17] [18] .
The FDA requires acetaminophen and all NSAIDs (to include both prescription or over the counter formulations) to carry a boxed warning regarding the potential adverse effects [19, 20] .
Other oral narcotics, opioids, and tramadol are also indicated for the treatment of OA [12] , but also carry risks of dependence and adverse side effects [21, 22] . A recent study of older adults found a higher incidence of fractures, hospital safety events, and all-cause mortality with opioid use compared with non-selective NSAIDs and coxibs [23] . The FDA has also issued warnings about the potential abuse of opioids [24] .
To alleviate OA pain quickly, IA injections of corticosteroids can be used, although the duration of effect wanes by week 4 [25] .
Continuous injection of steroids (once every 3 months) showed a marked decrease in the effectiveness after the first year [26] , and may produce destructive cartilage changes [27, 28] .
THE ROLE OF HYALURONANS AND HYLANS IN THE TREATMENT OF OA

Description of HAs and Hylans
Hyaluronan, a long-chain polymer of repeating disaccharides of sodium-glucuronate-Nacetylglucosamine, is found at high levels in joints, acting as a lubricant and shock absorber [29, 30] . Hylans are derivatives of hyaluronan (sodium hyaluronate) [29, 30] .
Clinical use of HAs and Hylans
Hyaluronan products are approved in the US for the treatment of pain associated with OA of the knee in patients who have not responded adequately to conservative non-pharmacologic therapy and to simple analgesics, such as acetaminophen and NSAIDs [29] [30] [31] [32] [33] [34] [35] (Tables 1 and 2 ) [29] [30] [31] [32] [33] [34] [35] . Table 2 illustrates the indicated number of injections for each product with their potential duration of effectiveness. [8, 39] . To decrease inflammation, HA suppresses the production and activity of pro-inflammatory mediators and proteases as well as alters the function of certain immune cells [7] . Histological evidence also
shows that HA prevents the degradation of cartilage and may promote its regeneration [7] . OA of the knee [7] . Many randomized controlled trials (described below) have demonstrated the effectiveness of HAs compared with placebo, although the clinical endpoints of these trials vary.
Randomized, Placebo-Controlled Studies
An early double-blind, randomized 12-week study compared the efficacy and tolerability of [55, 56] . An initial randomized, placebo-controlled trial by Tamir and colleagues [56] found that the HA provided similar relief to placebo. The FLEXX trial was a 26-week, randomized, double-blind, multicenter, controlled study of 588 subjects with knee OA randomized to 3-weekly IA injections of buffered saline or Euflexxa (20 mg/2 mL) [55] .
The primary outcome in this study was selfreported change from baseline in pain score following a 50-foot walk test [55] . Euflexxa provided significant and sustained (over 6 months) relief of knee pain, while also providing significant improvements in subject function, satisfaction with treatment, and health-related quality of life [55] . An extension of this trial showed that the pain reduction observed from initial injections of Euflexxa was sustained for an additional 23 weeks, suggesting that the efficacy of Euflexxa re-injection was comparable to that reported for re-injection of other HA agents [57] .
More recently, HA regimens have been reduced by the number of injections, with two HA products consisting of only one injection.
The formulation of Synvisc-One, a single, 6-mL injection of hylan G-F 20, was shown to be effective in a 26-week, randomized, doubleblind, placebo-controlled trial in patients with symptomatic knee OA [58] . In this study, one injection was effective in providing statistically significant, clinically relevant pain relief, as measured by WOMAC A1 (walking pain) over 26 weeks (Fig. 3 ) [58] . (Fig. 4) as early as 3 weeks through 13 weeks following a single injection [59] . No other endpoints measured were significantly different from placebo [59] . An extension study demonstrated that repeat HA treatment was as effective as initial therapy for an additional 13 weeks [60] ; however, no placebo comparison could be made for the repeat treatment as all patients in the extension study received the HA [60] .
Meta-Analyses
Several meta-analyses and systemic reviews have evaluated the efficacy of HAs in the treatment of pain from knee OA ( For example, Campbell and colleagues [66] compared the methodology of 6 systematic reviews examining the efficacy of HA versus placebo in the treatment of knee OA to determine the reasons for discrepant results among meta-analyses. According to this analysis, different trials were selected for inclusion in the meta-analyses due to differences in the electronic databases, search strategies, and selection criteria [66] . While similar methods for data extraction were used, differences were found in both the outcome measures and time points selected for extraction [66] . Moreover, methodological quality was not always formally assessed and different statistical methods for data synthesis resulted in conflicting estimates of efficacy [66] .
Collectively, these methodological differences may at least partly account for the discrepant results, especially with regard to the studies included in each analysis. Table 3 Summary of meta-analyses/systematic reviews of hylans/hyaluronic acids (Has) in knee osteoarthritis
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[ Fifty-nine patients were followed for up to 12 months, and 14 patients received a second course of treatment after 4-8 months [74] .
Patients who completed the study showed significant improvements in pain and duration of walking lasting 12 months; patients who required a second treatment cycle showed additional improvement [74] . Two other recent open-label extension studies found that repeat courses of HA led to additional reductions in patients' WOMAC pain scores after the first course of IA HAs. The rates of adverse events did not increase for the repeat courses of HA compared with adverse events reported with the first course of IA HAs [57, 60] .
In addition, in a post hoc analysis of results from a randomized trial of patients randomized to ''appropriate care with hylan G-F 20,'' and ''appropriate care without hylan G-F 20,'' patients who received hylan G-F 20 were subdivided into two groups: patients who received a single course and patients who received multiple courses [75] .
Both subgroups demonstrated significantly greater improvements in pain scores from baseline compared to the appropriate care group, with no differences between subgroups [75] . The number of local adverse events and rates of arthrocentesis were similar between patients who received a single or multiple courses of treatment [75] .
Two long-term studies also found benefit with repeat courses of hylan or HA injections over a 2-year period [76, 77] . Waddell and colleagues followed patients for up to 104 weeks and found 20% of patients reported pain relief with one course of hylan G-F 20 [77] . The mean time for the patients who required a second course was 19.6 months, with 75% of patients not needing the second course for a year or longer after the first course of injections [77] . All outcome measures significantly improved with repeat hylan G-F 20 injections, with a slightly higher incidence of local AEs [77] . An earlier study by Scali evaluated patients for a total of 30 months; patients were injected with a HA (Hyalart) weekly for 5 weeks every 6 months [76] . Repeated treatment cycles were associated with sustained improvement, which was more evident in patients with early stage OA [76] . No local or systemic AEs were reported [76] .
Finally, in a recent retrospective study of patients that received repeat injections of Supartz (sodium hyaluronate) for symptoms associated with knee OA, data were collected on 220 patients and 303 knee joints from 5 clinical sites [73] . Patients were at least 18 years of age with a confirmed diagnosis of OA and had received a minimum of one repeat treatment series of injections of Supartz in the affected knee [73] . In this study, repeat treatments were shown to delay the need for total knee arthroplasty for up to 4 years [73] . Before receiving sodium hyaluronate injections, approximately 94% of the patients rated their pain level as severe or moderate, but following repeat injections, 92% of patients demonstrated improvement in knee pain over time [73] . These data provide preliminary support for the favorable safety and efficacy profiles of repeat open-label pilot study [91] . In addition, a randomized, clinical trial of 60 patients found that treatment with Synvisc resulted in improved grip strength and pain in patients with CMC OA [92] .
EFFICACY OF VISCOSUPPLEMENTATION IN OTHER JOINTS
In CMC OA, Orthovisc was effective in reducing pain and more effective in improving some aspects of hand function compared with steroids [93] . A small pilot study showed that Hyalgan was also effective in CMC OA [94] .
Temporomandibular Joint
Research is still emerging in this area as very few studies have provided evidence of efficacy in treating OA of the temporomandibular joint. Currently, only hylan G-F 20 and Hyalgan have shown any positive effects. When given 14 days apart, two IA injections of Synvisc significantly reduced pain intensity versus two injections of corticosteroids [95] . Hyalgan has been found to markedly improve several outcomes (e.g., maximum mouth opening and movements, mastication efficiency, pain at mastication, pain at phonation, pain at rest, functional limitation, and subjective efficacy) over a 6-month period in a small open-label study of 76 patients when combined with arthrocentesis [96] .
Shoulder
A recent meta-analysis, which included randomized, controlled trials that compared the efficacy of HA injections with placebo, demonstrated that HAs are effective treatments for chronic shoulder pain [97] . Articles were identified through database searches where study endpoints included pain, shoulder range of motion, total functional score, and comparison between HA and steroid injections [97] . Based on 19 randomized trials that were pooled for analysis, HA injections were effective for alleviating chronic shoulder pain [97] . The primary outcome of global pain intensity was 
THE ROLE OF VS IN THE MULTIMODAL TREATMENT OF KNEE OA
The treatment of OA symptoms requires an integrated approach [38] and the combined use of both non-pharmacologic and pharmacologic treatments provide the greatest opportunity for pain relief and preservation of joint function.
Multimodal therapy has been shown to demonstrate superior efficacy when one OA treatment modality is combined with another [102] . A multimodal approach to the treatment of knee OA can provide excellent pain relief and a return to function [102] . By reducing pain through its impact on peripheral pain receptors and synovial tissue, as well as its role in enhancing the viscoelastic properties of synovial fluid, VS has become an integral part of the multimodal treatment of knee OA [3] . Numerous studies have shown that combined use of HAs plus conventional care including exercise is more effective than conventional care alone [103] [104] [105] [106] [107] . In addition, combining HAs with other pharmacotherapies can also be considered, as this approach has been shown to be effective [108, 109] . the OA treatment paradigm [3, [110] [111] [112] [113] [114] .
Patients with lower grades of OA reported a significantly (P\0.05) better or much better overall response to hylan G-F 20 than patients with higher grades of OA [111] , and patients with grade 3 OA found significantly (P\0.05) more reduced VAS pain scores than patients with Grade 4 OA in another study [112] .
Patients diagnosed with OA within a year were more likely to benefit from hylan G-F 20 than those patients who had been diagnosed longer than a year [114] . Evanich and colleagues found that patients treated with hylan G-F 20 with less severe radiographic OA were more likely to benefit from treatment than patients with more severe radiographic disease [113] . Compared with patients with more severe OA, patients with less severe disease who received an HA product required fewer analgesics or use of assistive devices [110] . Collectively these findings suggest that using HA soon after OA has been diagnosed could benefit patients.
In addition, HAs are at least as effective as NSAIDs if not more effective [3] , and have been shown to be safer than NSAIDs and COX-2 inhibitors [3, 16, 78, 115, 116] 
